We would like to highlight Adolor Corp. (NASDAQ: ADLR). The company is a development-stage biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. Adolor Corporation principal product candidate, Entereg (alvimopan), is designed to selectively block the unwanted effects of opioid analgesics on the gastrointestinal (GI) tract.
In the company’s news yesterday,
Adolor Corporation announced GlaxoSmithKline (GSK) returned the worldwide rights related to Entereg for chronic opioid bowel dysfunction (OBD), as well as rights related to Entereg for irritable bowel syndrome (IBS). While GSK will retain the rights to Entereg in regards to postoperative ileus (POI), Adolor will work with GSK to coordinate development and commercialization of Entereg for POI in the United States.
OBD is commonly described as constipation, but also includes other gastrointestinal effects such as abdominal cramping, bloating and gastroesophageal reflux. According to Michael R. Dougherty, president and CEO of Adolor, the company intends on addressing the needs for individuals affected by OBD.
“There is a large, unmet need for treatment options for the many patients who suffer with chronic OBD,” Dougherty stated in the press release. “Adolor maintains a portfolio of development candidates that may potentially serve this patient population, including Entereg, our Combination Product Program, and additional earlier stage compounds. We intend now to explore discussions with potential partners regarding this portfolio, and to submit to the FDA for review a protocol for an additional study of Entereg in OBD under a Special Protocol Assessment.
“We value our relationship with GSK for Entereg in POI a great deal and are pleased with the early progress of our efforts under the E.A.S.E. Program,” Dougherty added. “We will continue to work closely with GSK in implementing this program, and in making this important new product available to bowel resection patients and surgical teams.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
